In uncontrolled T2DM treated with a basal-bolus insulin regimen, weekly icodec was noninferior to daily glargine for HbA < sub > 1c < /sub > at 26 wk

Ann Intern Med. 2023 Aug 1. doi: 10.7326/J23-0058. Online ahead of print.ABSTRACTMathieu C, Ásbjörnsdóttir B, Bajaj HS, et al. Switching to once-weekly insulin icodec versus once-daily insulin glargine U100 in individuals with basal-bolus insulin-treated type 2 diabetes (ONWARDS 4): a phase 3a, randomised, open-label, multicentre, treat-to-target, non-inferiority trial. Lancet. 2023;401:1929-1940. 37156252.PMID:37523705 | DOI:10.7326/J23-0058

Source: Annals of Internal Medicine - July 31, 2023 Category: Internal Medicine Authors: Heiba Belal Gunjan Y Gandhi Source Type: research